Last reviewed · How we verify
omeprazole plus amoxicillin
Omeprazole reduces gastric acid while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection.
Omeprazole reduces gastric acid while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection. Used for Helicobacter pylori infection eradication, Peptic ulcer disease associated with H. pylori.
At a glance
| Generic name | omeprazole plus amoxicillin |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Proton pump inhibitor + beta-lactam antibiotic combination |
| Target | Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion, creating an environment where amoxicillin (a beta-lactam antibiotic) can effectively penetrate and eliminate H. pylori. This combination therapy is a standard first-line treatment for H. pylori eradication, typically used as part of triple or quadruple therapy regimens. The reduced acid environment enhances amoxicillin's bactericidal activity against the pathogen.
Approved indications
- Helicobacter pylori infection eradication
- Peptic ulcer disease associated with H. pylori
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Taste disturbance
- Allergic reaction (amoxicillin)
Key clinical trials
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (PHASE2)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease (NA)
- Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy (PHASE4)
- Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- omeprazole plus amoxicillin CI brief — competitive landscape report
- omeprazole plus amoxicillin updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI